Cyclerion Therapeutics (CYCN) Net Equity Issued and Repurchased (2025)
Cyclerion Therapeutics (CYCN) posted quarterly Net Equity Issued and Repurchased of $1.8 million for Q3 2025, up 30.91% quarter-over-quarter from $1.4 million in Q1 2025.
Cyclerion Therapeutics (CYCN) Net Equity Issued and Repurchased (2025) Analysis & Trends
Cyclerion Therapeutics' Net Equity Issued and Repurchased history runs 1 years deep, the most recent figure standing at $1.8 million for Q3 2025.
- In Q3 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $1.8 million; the TTM figure through Sep 2025 stood at $3.2 million (changed N/A YoY), while the FY2023 annual figure was $5.0 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased for Q3 2025 stood at $1.8 million, up from $1.4 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $1.8 million in Q3 2025, with the low at $1.4 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | 725,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 725,000.00 |
| Dec 31, 2025 | 725,000.00 |
| Sep 30, 2025 | 1.80 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Mar 31, 2025 | 1.38 Mn |